LCD Reference Article Response To Comments Article

Response to Comments: Treatment of Chronic Venous Insufficiency of the Lower Extremities

A58530

Expand All | Collapse All
Draft Article
Draft Articles are works in progress and not necessarily a reflection of the current billing and coding practices. Revisions to codes are carefully and thoroughly reviewed and are not intended to change the original intent of the LCD.

Document Note

Note History

Contractor Information

Article Information

General Information

Source Article ID
N/A
Article ID
A58530
Original ICD-9 Article ID
Not Applicable
Article Title
Response to Comments: Treatment of Chronic Venous Insufficiency of the Lower Extremities
Article Type
Response to Comments
Original Effective Date
11/12/2020
Revision Effective Date
N/A
Revision Ending Date
N/A
Retirement Date
N/A

CPT codes, descriptions, and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

N/A

Article Guidance

Article Text

The following are the comment summaries and contractor responses for First Coast Service Options Proposed Local Coverage Determination (LCD) DL38720 Treatment of Chronic Venous Insufficiency of the Lower Extremities which was posted for comment on 6/25/2020, and presented at the July 2020 Open Meeting. All comments were reviewed and incorporated into the final LCD where applicable.

Response To Comments

Number Comment Response
1

A comment was received recommending some updates to the first paragraph of the "History/Background and/or General Information" section of the LCD to remove “Chronic Venous Insufficiency (CVI) from sentence 2 and include “and have reflux >500 milliseconds “ in sentence 3.

We appreciate your comments, after further consideration and review; the LCD is revised with the recommended changes. Thank you.

2

Multiple comments were received regarding the third paragraph of the "Terminology of veins discussed within this LCD" section of the LCD recommending to add verbiage for pathologic perforator veins, remove circumflex veins and include the terms Anterior Accessory Great Saphenous Vein (AAGSV)’ and “Posterior Accessory Great Saphenous Vein (PAGSV).

Thank you for the comments. Upon review, the LCD is revised with these recommendations.

3

Multiple comments were received recommending changes to the "Invasive Procedures for the management of chronic venous insufficiency" section of the LCD in regards to Foam Sclerosant: Ultrasound-Guided Foam Sclerotherapy (UGFS) to include the different types of foam: physician-compounded foam (PCF) and non-compounded foam (NCF) also referred to as (polidocanol endovenous microfoam - PEM). It was also recommended to correlate these changes to reflect in the “Covered Indications” section of the Proposed LCD and to differentiate the CPT codes in the related billing and coding article.

We would like to thank you for your comments. The LCD is revised to reflect the difference between the types of foam: physician-compounded foam (PCF) and non-compounded foam (NCF). The related billing and coding article was updated to differentiate the appropriate CPT codes (36465 & 36466 is used for NCF and 36470 & 36471 is used for PCF).

4

Multiple comments were received recommending some changes to the "Covered Indications" section of the LCD regarding duplex scan criteria; to reword the sentence that contains “spontaneous” and to remove the 1000 ms requirement.

We would like to thank you for your comments. After further review, the LCD is revised with the recommended verbiage to clarify the duplex scan covered indication.

5

Multiple comments were received recommending some changes to number 3 of the "Covered Indications" section of the LCD to clarify incompetent perforator vein management criteria for circumstances such as;

  • An active venous ulcer is in close proximity to the IPV, OR
  • The proximal significant reflux has been treated and an IPV persists under or adjacent to a healed venous ulcer, OR
  • The proximal and regional venous reflux has been treated and there is persisting focal pain and tenderness or stasis dermatitis overlying an IPV, OR
  • The incompetent perforator demonstrates reflux >500 ms and diameter > 3.5 mm.

We would like to thank you for your comments. After further review of the LCD, the incompetent perforator vein management covered indication is revised to reflect the following circumstances;

  • An active venous ulcer is in close proximity to the IPV, OR
  • The proximal significant reflux has been treated and an IPV persists under or adjacent to a healed venous ulcer, OR
  • The proximal and regional venous reflux has been treated and there is persisting focal pain and tenderness or stasis dermatitis overlying an IPV, OR
  • The incompetent perforator demonstrates reflux >500 ms and diameter > 3.5 mm.
6

Multiple comments were received recommending some changes to number 5 and 6 of the "Covered Indications" section of the LCD to remove “tributary veins” from thermal ablation and chemical adhesive treatment.

We appreciate your comments. The LCD is revised to remove “tributary veins” from thermal ablation and chemical adhesive treatment in the “Covered Indications” section of the LCD.

7

Multiple comments were received recommending revising the phlebectomy treatment covered indication. Suggestions received mention that treatment can be “after or at the same time as” treatment of the saphenous vein and to allow phlebectomy for any patient that has symptomatic bulbous varicosities greater than 3mm diameter regardless of their relationship to the saphenous vein.

We appreciate your comments. After further consideration and review, the LCD is revised to include that phlebectomy treatment may be staged or concomitant and the relationship to the saphenous vein was removed.

8

Multiple comments were received recommending some changes to the "Professional Societies” and “Consultation Summary" section of the LCD in reference to appropriately identifying the Societies attending the Consultation Summary meetings and to reword some of the verbiage to fully capture the content of the meetings.

Thank you for your comments. After further consideration and review, the LCD is revised to include the appropriate Societies and representatives for the Consultation Summary meetings. The LCD is also revised to include "chemical/cyanoacrylate adhesive" in the "Professional Societies: American College of Phlebology" and "Consultation Summary" sections of the LCD.

9

A commenter submitted a presentation and FDA article in regards to "Retrograde Administration of Ultrasound-Guided Microfoam Chemical Ablation vs Endovenous Laser Ablation for the Treatment of Superficial Venous Insufficiency."

The presentation and FDA article were reviewed and we would like to thank you for the submission of this information.

10

A comment was received to reconsider eliminating the conservative treatment period requirement in the "Conservative management for chronic venous insufficiency (Noninvasive procedures)" section of the Proposed LCD.

We appreciate your comments, after further review, the LCD is revised to include conservative treatment requirements in the covered indications section of the LCD and in the plan of care documentation requirements section of the billing and coding article.

11

A comment was received to clarify the purpose of Radiofrequency ablation in the "Invasive Procedures for the management of chronic venous insufficiency" section of the LCD.

Thank you for your comments. After further consideration and review, the LCD is revised to include the purpose of RFA is to damage the collagen of the vein wall resulting in fibrosis and occlusion of a vein segment to eliminate reflux.

12

A comment was received recommending revision to the "Invasive Procedures for the management of chronic venous insufficiency" section of the LCD for the chemical adhesive to clarify the purpose and process of this treatment.

Thank you for your comments. After further consideration and review, the LCD is revised with the recommendation and the section regarding chemical adhesive was updated accordingly.

13

Multiple comments were received recommending some changes to the "Invasive Procedures for the management of chronic venous insufficiency: Sclerotherapy: Liquid Sclerosant" and "Limitations" section of the LCD in regards to liquid sclerotherapy to remove the limitation and clarify that it can be used when addressing telangiectasia and their feeding reticular veins with spontaneous and/or traumatic venous hemorrhage or when unique patient features suggest liquid sclerotherapy may be the safer option.

Thank you for your comments. After further consideration and review, the LCD is revised to remove limitation number two for liquid sclerotherapy. The LCD is also revised to clarify that liquid sclerotherapy can be used when addressing telangiectasia and their feeding reticular veins with spontaneous and/or traumatic venous hemorrhage or when unique patient features suggest liquid sclerotherapy may be the safer option.

14

A comment was received to remove the statement "Agents must be used per the FDA approved label," from the "Covered Indications" section of the Proposed LCD due to product labeling being an issue between the FDA and the industry. Commenter also stated that it should not be a determinant in CMS coverage policy.

Thank you for your comments. After further consideration and review, the LCD is revised to remove the drug label and FDA approved indications statement and link.

15

A comment was received recommending some changes to the "Covered Indications" section of the LCD in regards to the fourth bullet under indication number 2. The commenter suggested adding limited coverage for C1 disease and language regarding conservative therapy.

We appreciate your comment. After further review, the LCD is revised with the recommended changes.

16

A comment was received to include provider qualifications within the proposed LCD for physicians who are board certified in vascular surgery, interventional radiology, or interventional cardiology.

Thank you for your comment. After further review, the LCD is not going to be revised to include any provider qualifications. It is the responsibility of the provider to comply with all applicable State and Federal laws related to the human use of agents.

17

A comment was received that recommended that no more than 3 ablations be approved for any one leg over the course of 1 year and a 90-day global period on a leg following an ablation.

Thank you for your comment. Medicare established a national definition of a global surgical package to ensure that Medicare Administrative Contractors (MACs) make payments for the same services consistently across all jurisdictions. At this time, the ablation procedure codes have not been assigned a global period. After further review, the LCD and the billing and coding article documentation requirements is revised to clarify that a plan of care is for a 90 day episode of care.

18

Multiple comments were received in support of the proposed LCD and related billing and coding article.

We would like to thank you for your comments.

19

Multiple comments received in regards to the title of the LCD and related billing and coding article to include “Surgical,” stating that the LCD addresses surgical treatments and not medical management.

We would like to thank you for your comment. After review of the LCD, the title of the LCD will not reflect a change to include “Surgical”. However, the LCD and billing and coding article is revised to clarify that the plan of care, covered indications and documentation requirements apply to invasive procedures.

20

A comment was received to add ICD-10 diagnosis codes in relation to the listed venous malformations or other complex malformations.

Thank you for your comment. After review of the Draft Local Coverage Article: Billing and Coding: Treatment of Chronic Venous Insufficiency of the Lower Extremities, the Local Coverage Article (LCA) is revised to include the following ICD-10-CM code; Q27.8, Other specified congenital malformations of peripheral vascular system.

21

A comment was received to include non-physician licensed independent providers (nurse practitioners and physician assistants) to those who are allowed to perform procedures covered within the LCD.

We appreciate your comment. Provider types and provider qualifications are not included within the LCD. It is the responsibility of the provider to comply with all applicable State and Federal laws related to the human use of agents.

22

A comment was received to exclude the requirement that a venous clinical severity score (VCSS) be recorded for every patient.

We appreciate your comment. After review of the LCD, the decision was made to not exclude the requirement for venous clinical severity score (VCSS) for each patient.

23

A comment was received that the LCD suggests that Medicare will cover ultrasound guided foam sclerotherapy for the first time. Will a new code be created for this procedure or will RVUs be assigned to S2202?

We appreciate your comment. Medicare and other federal payers do not recognize “S” codes; however, S codes may be useful for claims to some private insurers. For the purposes of this LCD/LCA, Physician-compounded foam (PCF) sclerotherapy is reported using CPT codes 36470 and 36471. Non-compounded foam (NCF) sclerotherapy is reported using CPT codes 36465 and 36466.

N/A

Coding Information

Bill Type Codes

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Code Description

Please accept the License to see the codes.

N/A

CPT/HCPCS Codes

Please accept the License to see the codes.

N/A

CPT/HCPCS Modifiers

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-PCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Additional ICD-10 Information

Bill Type Codes

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Code Description

Please accept the License to see the codes.

N/A

Other Coding Information

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A N/A
N/A
Non-Excluded CPT/HCPCS Ended Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A

Revision History Information

Revision History Date Revision History Number Revision History Explanation
N/A

Associated Documents

Medicare BPM Ch 15.50.2 SAD Determinations
Medicare BPM Ch 15.50.2
Related National Coverage Documents
N/A
SAD Process URL 1
N/A
SAD Process URL 2
N/A
Statutory Requirements URLs
N/A
Rules and Regulations URLs
N/A
CMS Manual Explanations URLs
N/A
Other URLs
N/A
Public Versions
Updated On Effective Dates Status
11/06/2020 11/12/2020 - N/A Currently in Effect You are here

Keywords

N/A